Form 4: Fulgent Genetics CEO Ming Hsieh Terminates and Enters New Prepaid Variable Forward Agreement

Fulgent Genetics CEO Ming Hsieh, through the Ming Hsieh Trust, terminated a 2022 prepaid variable forward agreement and entered into a new agreement in March 2024, involving 1,000,000 shares of common stock.

Summary

• On March 8, 2024, the Ming Hsieh Trust terminated a prepaid variable forward agreement (the '2022 Agreement') with an unaffiliated bank for $23,381,900 in cash.
• The 2022 Agreement, entered into on June 8, 2022, obligated the Trust to deliver up to 1,000,000 shares of Fulgent Genetics' common stock in April 2025.
• In exchange for the 2022 Agreement, the Trust received $44,246,677.52 and pledged 1,000,000 shares as collateral.
• Concurrently, the Trust entered into a new prepaid variable forward agreement (the '2024 Agreement') with the same bank.
• The 2024 Agreement obligates the Trust to deliver up to 1,000,000 shares of common stock in March 2027.
• In exchange for the 2024 Agreement, the Trust received $17,302,606.00 and re-pledged 1,000,000 shares of common stock.
• Ming Hsieh, as trustee of the Ming Hsieh Trust, has sole voting and dispositive power over the securities held by the trust.
• The settlement terms of both agreements depend on the closing price of Fulgent Genetics' common stock on specified valuation dates.

Sentiment

Score: 5

Explanation: The document describes a financial transaction involving the CEO's trust. It's neutral in tone, simply reporting the facts of the agreement. The impact on the company is uncertain and depends on future stock performance.

Positives

• The termination of the 2022 agreement provided the Trust with $23,381,900 in cash.
• The new 2024 agreement provided the Trust with $17,302,606.00 in cash.
• The Trust retains voting rights for the pledged shares under both agreements.

Negatives

• The Trust is obligated to deliver up to 1,000,000 shares of common stock under the 2024 agreement, potentially diluting shareholder value.
• The settlement terms of the agreements are subject to market fluctuations, which could result in unfavorable outcomes for the Trust.

Risks

• Fluctuations in the market price of Fulgent Genetics' common stock could impact the settlement value of the forward agreements.
• The obligation to deliver shares under the 2024 agreement could potentially dilute shareholder value.
• The terms of the agreements are complex and involve financial risk for the Trust.

Future Outlook

The Trust is obligated to deliver up to 1,000,000 shares of Fulgent Genetics' common stock in March 2027 under the 2024 Agreement, with the exact number of shares depending on the stock price at that time.

Industry Context

Prepaid variable forward agreements are often used by company insiders to monetize their holdings while retaining voting rights and deferring capital gains taxes. The termination and replacement of the agreement suggest a change in the insider's financial strategy or outlook on the company's stock.

Comparison to Industry Standards

• Prepaid variable forward agreements are a relatively common tool used by executives at publicly traded companies to manage their personal finances and holdings.
• Similar transactions have been undertaken by executives at companies like Tesla (Elon Musk) and Amazon (Jeff Bezos), although the specific terms and conditions vary widely based on individual circumstances and market conditions.
• The floor and cap prices in these agreements are typically set based on the current market price of the stock and the desired level of risk and reward for the executive.

Stakeholder Impact

• Shareholders may be impacted by potential dilution if the Trust is required to deliver a significant number of shares under the 2024 Agreement.
• The transaction could affect the perceived stability of the company's stock price.

Key Dates